US Non Alcoholic Steatohepatitis (NASH) Therapeutics Market Report 2023 to 2030

US Non Alcoholic Steatohepatitis (NASH) Therapeutics Market Analysis

$ 3999

US Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A number of factors, including the rising prevalence of non-alcoholic steatohepatitis, the rising incidence of chronic illnesses linked to it, the rising adoption of sedentary lifestyles, the rising awareness of health issues, etc., have contributed to the growth of the non-alcoholic steatohepatitis market over the past few years. Major global players in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market are Intercept Pharmaceuticals, Inc. Novartis AG,Siemens Healthineers AG, AstraZeneca PLC, Galectin Therapeutics Inc., GENFIT S.A., Madrigal Pharmaceuticals, Inc., Inventiva S.A., ONE WAY LIVER, S.L., Galmed Pharmaceuticals Ltd., Cirius Therapeutics, Prometheus Laboratories Inc., BioPredictive.

ID: IN10USRD054 CATEGORY: Rare Diseases GEOGRAPHY: US AUTHOR: Sakshi Mantri

Buy Now

US Non Alcoholic Steatohepatitis (NASH) Therapeutics Market Analysis Summary

US Non Alcoholic Steatohepatitis (NASH) Therapeutics Market is valued at around $0.48 Bn in 2022 and is projected to reach $5.96 Bn by 2030, exhibiting a CAGR of 37.2% during the forecast period 2023-2030.

Non-alcoholic steatohepatitis (NASH), an inflammatory liver condition, is characterised by hepatocellular swelling, inflammation, and excessive fat deposition in the liver (steatosis). Non-Alcoholic Steatohepatitis, also referred to as "Silent Liver Disease," is a liver disease caused by chronic alcohol use, however, it primarily affects those who abstain from alcohol or only consume it in extremely small doses. Non-alcoholic steatohepatitis is the term for the second stage of non-alcoholic fatty liver disease (NAFLD), which has caused liver inflammation and cell death (NASH). The development of new pharmaceuticals, rising consumption of processed foods rich in fructose and polyunsaturated fatty acids, increased investment in medical infrastructure, and the proliferation of businesses offering non-invasive diagnostic methods are all expected to contribute to the market's expansion for Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market. Major global players in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market are Intercept Pharmaceuticals, Inc. Novartis AG, Siemens Healthineers AG, AstraZeneca PLC, Galectin Therapeutics Inc., GENFIT S.A., Madrigal Pharmaceuticals, Inc., Inventiva S.A., ONE WAY LIVER, S.L., Galmed Pharmaceuticals Ltd., Cirius Therapeutics, Prometheus Laboratories Inc., BioPredictive.

Market Dynamics

Market Drivers

Along with cases of its associated chronic diseases, sedentary lifestyle adoption, greater health consciousness, and other factors, non-alcoholic steatohepatitis prevalence is rising. As a result, over the past few years, the non-alcoholic steatohepatitis market has been growing. If NASH is not treated, it can lead to cirrhosis and liver cancer. Chronic liver inflammation is a feature of NASH. Because they are more likely to have other symptoms (when two or more medical conditions are present), such as high blood pressure and coronary artery disease, patients with NASH are more likely to have a heart attack or stroke in addition to having an increased risk for liver-related illnesses. The non-alcoholic steatohepatitis market is developing internationally as a result of the rising number of NASH patients and the rising demand for NASH medications.

Market Restraints

The development of the market may be hampered by a lack of reliable and accessible diagnostic procedures, issues with regulatory compliance, and other considerations. NASH is now diagnosed via liver biopsies, imaging studies, and time-consuming, challenging diagnostic techniques such as blood testing. Due to the intrusive nature of liver biopsy, which entails high expenses, sampling errors, and considerable risks including bleeding, discomfort, perforation, infection, and even (rarely) death, many patients choose not to receive a diagnosis. In turn, this slows the rate of NASH diagnoses and limits the market's growth for non-alcoholic steatohepatitis worldwide.

Key players

Intercept Pharmaceuticals, Inc. Genfit SA Gilead Sciences, Inc. Allergan (AbbVie Inc.) Novartis AG Galmed Pharmaceuticals Ltd. Pfizer Inc. Bristol Myers Squibb Company Madrigal Pharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For US Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market

By Drug Type

vitamin E
pioglitazone
ocaliva,
elafibranor
selonsertib
cenicriviroc
obeticholic
others

By Disease Cause

Hypertension
Heart Disease
High Blood Lipid
Type 2 Diabetes
Obesity

By Diagnostics:

Imaging Techniques
Diagnostic Tests
Biopsy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.